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Abstract
Objective. To investigate the prevalence and type distribution of human papillomavirus (HPV) in women with normal
cervical cytology and with cervical intraepithelial neoplasia I to III(CIN) or carcinoma of the cervix in Okinawa, Japan.
Methods. We investigated HPV DNA in 4,078 subjects with cytologically normal cervices, 279 subjects with CIN, and 383
subjects with cervical cancer in Okinawa Prefecture in Japan. The presence of HPV DNA was also compared among
generations. HPV DNA was both detected and typed using polymerase chain reaction (PCR).
Results. The HPV positivity rate was 10.6% in the subjects who were normal on cervical cytodiagnosis. In each generation,
the positivity rate was 20.4% in women aged 20–29 years and approximately 10% in the groups aged 30–89 years, with
signiﬁcant differences among generations. The HPV positivity rates in CIN and cervical cancer groups were 76.0% and
86.2%, respectively, with no signiﬁcant difference between the groups. The positivity rate of HPV 16 decreased with age in
both CIN and cervical cancer groups.
Conclusion. Among non-cancer subjects, HPV infection rates were almost 20% in women aged 20–29 years and 10% in
women aged 30–89 years. HPV16-positive CIN or carcinoma were more prevalent in the younger women, suggesting that
HPV16-infected epithelial cells rapidly progress to cervical cancer.
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Introduction
Although it is obvious that HPV is closely involved in
the development of uterine cervical cancer, the
reasons for onset of cervical cancer are not well
understood. There have been only a few reports of
the HPV prevalence rate in the uterine cervix in
healthy women in Japan. A documentation of the
prevalence might help in identifying the early phases
of the disease, as well as contributing to an under-
standing of the natural history of HPV infection.
Such information could be important in preventing
the HPV infection and its consequences.
Several types of HPV associated with anogenital
lesions have been identiﬁed in cervical specimens.
These types, such as 16, 18, 31, 33, 35 and 58, are
referred to as cervical carcinoma-associated HPVs.
In Okinawa Prefecture, the prevalence rate of
cervical cancer is the highest in Japan. The prefecture
is located about 1,500 km from the main islands of
Japan, and is a relatively closed colony with little
population exchange with the main Japanese islands.
Here we performed a large-scale epidemiological
survey in which both the prevalence rate and the types
of HPV were investigated. Healthy women and
women with CIN or cervical cancer were included in
this study.
Materials and methods
The study population was selected from women who
underwent cervical cancer screening between 1994
and 1995, 4,078 subjects were normal on cervical
cytodiagnosis. Additional subjects included 279
women with CIN and 383 women with cervical
cancer, who visited the obstetrics and gynecology
(OB-GY) outpatient department of Ryukyu Univer-
sity Hospital between January 1993 and September
1998. Consent was obtained for HPV testing. For
HPV DNA detection, DNA was extracted from cells
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DOI: 10.1080/10647440400028151collected on cervical swabs and ampliﬁed by PCR
using HPVL1 consensus primers [1]. The HPV
DNA was typed using type-speciﬁc primers (16, 18,
31, 33, 35, 58) [2]. Undetermined types were
referred to as HPV X.
Results
The HPV positivity rate was 10.6% in the subjects
who were normal on cytodiagnosis. When analyzed
by generation, the positivity rate peaked at a rate of
20.4% in the 20–29 years age group, and persisted at
a rate of about 10% after the age of 30 years up to 89
years (Table I). The rates were signiﬁcantly different
between the group aged 20–29 years and the group
aged 30–39 to 70–79 years (p50.001). There was
no signiﬁcant difference between the groups aged
20–29 years and 80–89 years, because of the small
number of cases. The frequencies of the high-risk
HPV types (16, 18), intermediate-risk types (31, 33,
35, 58), and unknown (X) types were 0.3% (13/
4,078), 1.3% (53/4,078), and 9.0% (368/4,078),
respectively. As shown in Table I, type 35 was the
most frequently detected known HPV type and type
18 was the least frequently detected type in the
cytologically normal females.
The HPV positivity rate was 76.0% in CIN group,
and the positivity rate by generation ranged from
61.5% to 88.9% (Table II). Among the HPV types,
the frequency of type 16 was the highest at 19.3%,
and type 18 had the lowest frequency at 1.4% in the
HPV-positive subjects. Type X accounted for 63.2%.
The type 16 positivity rate by generation was 40.6%
in the 20–29 and 20.7% to 6.3% in the 30–59-year-
old women, demonstrating a decrease with age.
The overall HPV positivity rate was 85.6% in the
cervical cancer group, and the rate by generation
ranged from 76.1% to 95.0% (Table III). Among the
known HPV types, the 33.6% frequency of type 16
was the highest, followed by 7.3% for type 33, 6.1%
for type 31, 5.8% for type 58, 3.9% for type 18 and
2.7% for type 35. The 40.6% frequency of type X
was signiﬁcantly lower than in the CIN group
(p50.0001). The frequency of HPV type 16
decreased from 42.1 to 63.3% in the group who
were 20–39 years of age to 9.5% in the oldest group
who were 80–89 years of age.
Discussion
The mortality rate of cervical cancer has been
decreasing, because of both the increased use of
Table I. HPV prevalence by age in cytologically normal cervical swabs.
HPV types (%)*
Age (years) No. of cases No. HPV+ (%) 16 18 31 33 35 58 X
20–29 275 56 (20.4) 3 (5.4) 0 (0) 4 (7.1) 0 (0) 4 (7.1) 0 (0) 48 (85.7)
30–39 564 51 (9.0) 0 (0) 0 (0) 2 (3.9) 0 (0) 5 (9.8) 0 (0) 44 (86.3)
40–49 802 73 (9.1) 2 (2.7) 0 (0) 0 (0) 3 (4.1) 5 (6.8) 2 (2.7) 61 (83.6)
50–59 1039 104 (10.0) 2 (1.9) 1 (1.0) 2 (1.9) 3 (2.9) 4 (3.8) 2 (1.9) 90 (86.5)
60–69 1029 112 (10.9) 3 (2.7) 1 (0.9) 2 (1.8) 2 (1.8) 4 (3.6) 4 (3.6) 96 (85.7)
70–79 357 36 (10.1) 1 (2.8) 0 (0) 0 (0) 2 (5.6) 3 (8.3) 0 (0) 30 (83.3)
80–89 15 2 (13.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100)
Total 4078 434 (10.6) 11 (2.5) 2 (0.5) 10 (2.3) 10 (2.3) 25 (5.8) 8 (1.8) 368 (84.8)
X, HPV type not determined; *, HPV type/HPV(+) in each generation.
Table II. HPV prevalence by age in CIN I–III.
HPV types (%)*
Age (years) No. of cases No. HPV+ (%) 16 18 31 33 35 58 X
20–29 39 32 (82.1) 13 (40.6) 0 (0) 1 (3.1) 1 (3.1) 0 (0) 0 (0) 17 (53.1)
30–39 106 82 (77.4) 17 (20.7) 2 (2.4) 7 (8.5) 2 (2.4) 0 (0) 4 (4.9) 50 (61.0)
40–49 71 53 (74.6) 9 (17.0) 1 (1.9) 2 (3.8) 3 (5.7) 3 (5.7) 2 (3.8) 33 (62.3)
50–59 26 16 (61.5) 1 (6.3) 0 (0) 0 (0) 0 (0) 1 (6.3) 1 (6.3) 13 (81.3)
60–69 18 16 (88.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 16 (100)
70–79 16 10 (62.5) 1 (10.0) 0 (0) 2 (20.0) 2 (20.0) 0 (0) 0 (0) 5 (50.0)
80–89 3 3 (100) 0 (0) 0 (0) 1 (33.3) 1 (33.3) 1 (33.3) 0 (0) 0 (0)
Total 279 212 (76.0) 41 (19.3) 3 (1.4) 13 (6.1) 9 (4.2) 5 (2.4) 7 (3.3) 134 (63.2)
X, HPV type not determined; *, HPV type/HPV(+) in each generation.
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effective therapies. However, despite these advances,
about 5,000 women die yearly in Japan of cervical
cancer. Cervical cancer remains an important gyne-
cological problem. Since Zur Hausen’s group [3]
detected HPV in cervical cancer tissues in 1983, it
has become well recognized that HPV is the major
risk factor for the development of cervical cancer.
Much basic information about HPV and many
clinical studies have been reported in the literature
[4–6]. However, neither deﬁned preventive measures
nor therapeutic methods targeting HPV have been
established. Since the mechanism of carcinogenesis
after HPV infection has not been fully elucidated, it
is very important epidemiologically to survey the
HPV prevalence rate and types in the normal uterine
cervix, in CIN and in cervical cancer in each
generation.
In this study, on analysis of HPV positivity in
cervical cytology-normal women by age, the positiv-
ity rate peaked to 20.4% in the group aged 20–29
years, and persisted at about 10% in the groups aged
30–39 to 80–89 years. This ﬁnding was signiﬁcant
because it showed that infection occurred in young
women aged 20–29 years at a rate which decreased
by about half at ages 30–39 years, probably by
elimination of unknown immunological mechan-
isms, and then persisted in women up to the age of
80–89 years. Therefore, although the prevalence of
cervical cancer decreased in the group aged 80–90
years, HPV-positive individuals had the risk of
developing cervical cancer.
On analysis of the frequencies of the HPV types in
the subjects who were normal on cervical cytodiag-
nosis, type X dominated and accounted for 84.8%,
suggesting that the change from infection to malig-
nancy might be infrequent. Melkert et al. [7]
reported that the positivity rate was 10.7% in 4,146
subjects who had a normal cervical cytodiagnosis.
The rates of 13.9% in subjects aged 15–34 years and
6.6% in subjects 35–55 years old were signiﬁcantly
different, suggesting that juvenile HPV infection was
transient. Devilliers et al. [8] also reported that the
positivity rate peaked to 17.8% in individuals aged
20–24 years, and fell to 13.3% in subjects aged 25–
29 years, 10% in subjects aged 30–49 years, 6.1% in
subjects aged 50–54 years and 3.0% in 55–80-year-
old subjects. They hypothesized that the differences
in the positivity rates among the various age groups
were related to the extent of sexual activity,
presumably higher in the younger individuals.
The HPV positivity rates of CIN and cervical
cancer in this study were similar to rates reported
in other studies [9]. About 90 types of HPV have
been identiﬁed to date. The frequency of type 16
was the highest and type 18 was lowest among the
HPV types detected in CIN. It is acknowledged
that detection of HPV18 infections in CIN is
difﬁcult because of the rapid progress of the
condition, and this may be reﬂected in the low
frequency of detection. In cervical cancer, type 16
was the most frequent (33.6%), type 35 was the
least frequent (2.7%) and type 18 frequency was
3.9%. These ﬁndings in cervical cancer were
similar to those of other studies of patients in
Japan. However, the frequencies of types 16 and
18 in the USA were 47.1% and 23.5%, respec-
tively [10]. According to data collected from 22
different countries by Bosch and colleagues [11],
detection rates for type 16 and type 18 were 50%
and 14%, respectively. Therefore, the positivity
rates by type differed from those in this study,
suggesting that geographic, racial and environmen-
tal factors are related to the prevalence of HPV
types. The positivity rate of type 16 was the highest
in CIN and cervical cancer. The type 16 positivity
rate by generation decreased with age in both CIN
and cervical cancer groups. These ﬁndings sug-
gested that the relatively rapid progress of the
cervical lesion after infection was due to the high-
risk type 16. Therefore, HPV 16-positive young
women with CIN should be carefully managed.
Table III. HPV prevalence by age in cervical cancer.
HPV types (%)*
Age (years) No. of cases No. HPV+ (%) 16 18 31 33 35 58 X
20–29 20 19 (95.0) 8 (42.1) 3 (15.8) 1 (5.3) 3 (15.8) 0 (0) 1 (5.3) 3 (15.8)
30–39 67 60 (89.6) 38 (63.3) 3 (5.0) 2 (3.3) 3 (5.0) 4 (6.7) 6 (10.0) 4 (6.7)
40–49 86 73 (84.9) 27 (37.0) 4 (54.8) 4 (54.8) 2 (2.7) 2 (2.7) 1 (1.4) 33 (45.2)
50–59 71 54 (76.1) 19 (35.2) 0 (0) 3 (5.6) 3 (5.6) 0 (0) 4 (7.4) 25 (46.3)
60–69 78 68 (87.1) 14 (20.6) 3 (4.4) 5 (7.4) 11 (16.2) 3 (4.4) 3 (4.4) 29 (42.6)
70–79 38 35 (92.1) 3 (8.6) 0 (0) 2 (5.7) 2 (5.7) 0 (0) 2 (5.7) 26 (74.3)
80–89 23 21 (91.3) 2 (9.5) 0 (0) 3 (14.3) 0 (0) 0 (0) 2 (9.5) 14 (66.7)
Total 383 330 (86.2) 111 (33.6) 13 (3.9) 20 (6.1) 24 (7.3) 9 (2.7) 19 (5.8) 134 (40.6)
X, HPV type not determined; *, HPV type/HPV(+) in each generation.
HPV infection in uterine cervix 79Cervical cancer begins with HPV infection of the
uterine cervix. Elucidation of the mechanism by
which HPV progresses from infection to cervical
cancer is necessary for the prevention of infection
and effective therapeutic intervention after infec-
tion.
References
1. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M,
Yoshikura H, Iwamoto A. Detection and typing of multiple
genital human papillomaviruses by DNA ampliﬁcation with
consensus primer. Jpn J Cancer Res 1991;82:524–531.
2. Asato T, Nakajima Y, Nagamine M, Nakashima Y, Takei H,
Maehama T. Correlation between the progression of cervical
dysplasia and the prevalence of human papillomavirus. J
Infect Dis 1994;169:940–941.
3. Durst M, Gissman L, Ikenberg H, zur Hausen H. A
papillomavirus DNA from a cervical carcinoma and its
prevalence in cancer biopsy samples from different geo-
graphic regions. Proc Natl Acad Sci USA 1983;80:3812–
3815.
4. zur Hausen H. Papillomaviruses in anogenital cancer as a
model to understand the role of viruses in human cancers.
Cancer Res 1989;49:4677–4681.
5. Herckenrode C, Malcolm A, Coleman D. Prevalence of
human papillomavirus (HPV) infection in Basque country
women using slot-blot hybridization: a survey of women at
low risk of developing cervical cancer. Int J Cancer
1992;51:581–586.
6. Woodman C, Collins S, Winter H, Baily A, Ellis J, Prior P,
Natural history of cervical human papillomavirus infection in
young women: a longitudinal cohort study. Lancet
2001;357:1831–1836.
7. Melkert PWJ, Hopman E, Van Den Blule AJC, Risse EKJ,
Van Diest PJ, Bleker OP. Prevalence of HPV on cytomor-
phologically normal cervical smears, as determined by the
polymerase chain reaction, is age-dependent. Int J Cancer
1993;53:919–923.
8. De Villiers EM, Wagner D, Schneider A, et al. Human
papillomavirus DNA in women without and with cytological
abnormalities: results of a 5-year follow-up study. Gynecol
Oncol 1992;44:33–39.
9. Sasagawa T, Dong Y, Saijoh K, Satake S, Tateno M, Inoue
M. Human papillomavirus infection and risk determinants
for squamous intraepithelial lesion and cervical cancer in
Japan. Jpn J Cancer Res 1997;88:376–384.
10. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancester
W, Kurman RJ. Human papillomavirus infection of the
cervix: relative risk associations of 15 common anogenital
types. Obstet Gynecol 1992;79:328–337.
11. Bosch FX, Manos MM, Munoz N, et al. Prevalence of
human papillomavirus in cervical cancer: a worldwide
perspective. J Natl Cancer Inst 1995;78:796–802.
80 T. Maehama